Actively Recruiting
Helical Tomotherapy in Multiple Myeloma
Led by Fuling Zhou · Updated on 2023-08-01
58
Participants Needed
1
Research Sites
237 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To explore the safety and efficacy of systemic radiotherapy (TBI) combined with melphalan (Mel) for pretreatment of autologous hematopoietic stem cells in multiple myeloma.
CONDITIONS
Official Title
Helical Tomotherapy in Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Multiple myeloma patients receiving induction therapy and stem cell mobilization preparation for autologous transplantation
- Agreement to comply with all contraceptive requirements
- ECOG performance status of 2 or less
- Total bilirubin, ALT, and AST less than 2 times the upper limit of normal
- Blood urea nitrogen (BUN) less than 30 mg/dL
- At least 2 x 10^6 CD34+ cells per kg collected
- Absolute neutrophil count greater than 1000/uL and platelet count greater than 100,000/uL
- Expected survival time of more than 3 months
- Written informed consent obtained from the patient or their immediate family
You will not qualify if you...
- Inability to tolerate melphalan and radiotherapy as judged by the investigator
- Known active hepatitis B virus, hepatitis C virus, or seropositive for HIV
- Uncontrolled or severe cardiovascular disease
- Serious physical or mental illness as judged by the investigator or protocol
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China, 430071
Actively Recruiting
Research Team
F
Fuling Zhou
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here